@grlchld's GLP-1 content needs more context, we checked

What did @grlchld actually say?

The creator says they decided against trying Ozempic after concluding it was "just an appetite suppressant." Their reasoning: "I'll eat right through that. It won't work." This is a confident dismissal based on a fairly narrow understanding of how GLP-1 receptor agonists actually function in the body. To be fair, the appetite piece isn't wrong. But it's about 20% of the story.

The claim lands in a gray zone. It's not fabricated, but it's reductive enough to be misleading, especially to 5 million viewers who may be making real medical decisions based on a 15-second take. Let's unpack what semaglutide actually does and whether the "I'll eat right through it" logic holds up scientifically.

Does the science back this up?

Not really. GLP-1 receptor agonists work through several overlapping mechanisms, and appetite suppression is only one of them. The short answer is: most people cannot simply "eat right through" semaglutide, and the clinical trial data backs that up pretty clearly.

Semaglutide works by binding to GLP-1 receptors in the brain, gut, and pancreas. It slows gastric emptying, meaning food stays in your stomach longer. It also acts on the hypothalamus and brainstem to reduce hunger signaling. Critically, it triggers a satiety response that is largely involuntary. Wilding et al. (2021, New England Journal of Medicine) found that participants on 2.4mg semaglutide lost an average of 14.9% of body weight over 68 weeks, versus 2.4% on placebo. These were adults with obesity, not a hand-picked sample. The drug produced results because it changed the physiological experience of hunger and fullness, not just willpower.

What did they get wrong (or right)?

They got the mechanism partially right but drew the wrong conclusion. Yes, appetite suppression is a real and documented effect of semaglutide. But saying it's "just an appetite suppressant" misses the gastric motility component, the neurological satiety signaling, and the insulin-glucagon regulation that makes the drug effective even in people who consider themselves resistant to feeling full.

The "I'll eat right through that" framing assumes the drug works the same way willpower or a diet does. It doesn't. Gastric emptying slows measurably on semaglutide, meaning the physical capacity to eat large volumes decreases regardless of psychological intent. Davies et al. (2021, The Lancet) documented that GLP-1 agonists reduce caloric intake through both central and peripheral pathways. The creator's logic would make sense if appetite suppression were purely psychological. It's not. That's the key error here.

What should you actually know?

If you've ever told yourself you could "eat through" any medication or diet, you're not alone. But GLP-1 receptor agonists are not a willpower aid. They change the physiology of hunger in ways that are genuinely different from stimulant-based appetite suppressants like older diet drugs.

A few things worth knowing:

• Semaglutide slows gastric emptying, which creates physical fullness independent of mental discipline (Nauck et al., 2021, Diabetes Care).
• The drug acts on the brain's reward circuitry, reducing the appeal of high-calorie foods, not just the frequency of hunger signals.
• Some people do experience reduced efficacy over time or find certain foods still trigger overeating. This is real, but it's not the same as "eating right through" the medication.
• GLP-1 medications are not uniformly effective for everyone, and response rates vary. But dismissing them based on a misread of their mechanism isn't a good reason to opt out.

If you're considering a GLP-1 medication, talk to a licensed clinician who can assess your specific history. The decision deserves more than a TikTok take.